A detailed history of Sei Investments CO transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Sei Investments CO holds 39,864 shares of APLS stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,864
Previous 25,333 57.36%
Holding current value
$1.39 Million
Previous $1.52 Million 54.55%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$55.39 - $72.47 $804,872 - $1.05 Million
14,531 Added 57.36%
39,864 $2.34 Million
Q4 2023

Feb 14, 2024

SELL
$37.14 - $64.82 $272,607 - $475,778
-7,340 Reduced 22.47%
25,333 $1.52 Million
Q3 2023

Nov 14, 2023

SELL
$23.65 - $89.22 $772,456 - $2.91 Million
-32,662 Reduced 49.99%
32,673 $1.24 Million
Q2 2023

Aug 11, 2023

BUY
$76.68 - $93.31 $1.08 Million - $1.32 Million
14,140 Added 27.62%
65,335 $5.95 Million
Q1 2023

May 12, 2023

BUY
$46.59 - $66.96 $1.88 Million - $2.71 Million
40,399 Added 374.2%
51,195 $3.38 Million
Q4 2022

Feb 10, 2023

SELL
$43.24 - $61.04 $1.95 Million - $2.75 Million
-45,125 Reduced 80.69%
10,796 $558,000
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $2.5 Million - $3.9 Million
55,921 New
55,921 $3.82 Million
Q3 2021

Nov 12, 2021

SELL
$31.4 - $69.84 $617,763 - $1.37 Million
-19,674 Closed
0 $0
Q2 2021

Aug 06, 2021

BUY
$40.9 - $64.9 $139,305 - $221,049
3,406 Added 20.94%
19,674 $1.24 Million
Q4 2020

Feb 08, 2021

BUY
$30.79 - $57.2 $500,891 - $930,529
16,268 New
16,268 $931,000
Q2 2020

Aug 11, 2020

SELL
$24.8 - $38.49 $193,068 - $299,644
-7,785 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$17.91 - $44.33 $139,429 - $345,109
7,785 New
7,785 $209,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.84B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.